Antibiotic_JJ Pharmacodynamics_NN in_IN Surgical_NP Prophylaxis_NP :_: an_DT Association_NN between_IN Intraoperative_JJ Antibiotic_JJ Concentrations_NNS and_CC Efficacy_NN The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO characterize_VB the_DT relationship_NN between_IN gentamicin_NN concentrations_NNS during_IN surgery_NN and_CC the_DT development_NN of_IN wound_NN infection_NN following_VBG colorectal_JJ operations_NNS ._SENT Despite_IN decades_NNS of_IN research_NN in_IN surgical_JJ prophylaxis_NN ,_, the_DT relationship_NN between_IN intraoperative_JJ antibiotic_JJ concentrations_NNS and_CC postoperative_JJ infection_NN and_CC the_DT concentrations_NNS required_VBN for_IN effective_JJ prophylaxis_NN have_VBP not_RB been_VBN established_VBN ._SENT A_DT pharmacodynamic_JJ analysis_NN was_VBD conducted_VBN using_VBG data_NNS from_IN a_DT previous_JJ prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ clinical_JJ study_NN which_WDT compared_VBD two_CD dosage_NN regimens_NNS of_IN gentamicin_NN plus_CC metronidazole_NN for_IN prophylaxis_NN in_IN connection_NN with_IN elective_JJ colorectal_JJ surgery_NN ._SENT Univariate_JJ and_CC multivariate_JJ analyses_NNS of_IN risk_NN factors_NNS for_IN postoperative_JJ wound_NN infection_NN were_VBD conducted_VBN ,_, and_CC the_DT relationship_NN between_IN intraoperative_JJ gentamicin_NN concentrations_NNS and_CC surgical_JJ outcome_NN was_VBD characterized_VBN ._SENT The_DT gentamicin_NN concentration_NN at_IN the_DT time_NN of_IN surgical_JJ closure_NN was_VBD one_CD of_IN the_DT strongest_JJS independent_JJ risk_NN factors_NNS for_IN infection_NN (_( P_NN =_SYM 0.02_CD )_) ,_, along_RB with_IN the_DT presence_NN of_IN diabetes_NN mellitus_NN (_( P_NN =_SYM 0.02_CD )_) ,_, stoma_NN (_( P_NN =_SYM 0.04_CD )_) ,_, and_CC advanced_JJ age_NN (_( P_NN =_SYM 0.05_CD )_) ._SENT Gentamicin_NN concentrations_NNS at_IN closure_NN of_IN less_JJR than_IN 0.5_CD mg/liter_NN were_VBD associated_VBN with_IN an_DT infection_NN rate_NN of_IN 80_CD %_NN (_( representing_VBG 8_CD of_IN 10_CD patients_NNS with_IN concentrations_NNS below_IN that_DT level_NN )_) (_( P_NN =_SYM 0.003_CD )_) ._SENT Receiver_NN operating_VBG characteristic_JJ curve_NN analysis_NN identified_VBD a_DT critical_JJ closure_NN concentration_NN of_IN 1.6_CD mg/liter_NN for_IN effective_JJ surgical_JJ prophylaxis_NN (_( P_NN =_SYM 0.002_CD ;_: sensitivity_NN ,_, 70.8_CD %_NN ;_: specificity_NN ,_, 65.9_CD %_NN )_) ._SENT This_DT study_NN provides_VBZ new_JJ and_CC important_JJ information_NN on_IN antibiotic_JJ pharmacodynamics_NNS in_IN surgical_JJ prophylaxis_NN ._SENT It_PP demonstrates_VBZ the_DT critical_JJ effect_NN of_IN the_DT antibiotic_JJ concentration_NN at_IN closure_NN on_IN wound_NN infection_NN and_CC suggests_VBZ a_DT significant_JJ association_NN between_IN the_DT concentration_NN and_CC other_JJ well-established_JJ risk_NN factors_NNS ,_, like_IN the_DT timing_NN of_IN preoperative_JJ antibiotic_JJ administration_NN and_CC surgery_NN duration_NN ._SENT Surgical_JJ site_NN infections_NNS ,_, a_DT significant_JJ postoperative_JJ complication_NN ,_, can_MD lead_VB to_TO considerable_JJ patient_JJ morbidity_NN and_CC mortality_NN ._SENT Wound_NN infections_NNS account_VBP for_IN 38_CD %_NN of_IN surgical_JJ infections_NNS and_CC 17_CD %_NN of_IN all_DT nosocomial_JJ infections_NNS ._SENT The_DT benefits_NNS of_IN preoperative_JJ antibiotics_NNS ,_, which_WDT reduce_VBP bacterial_JJ contamination_NN during_IN clean-contaminated_JJ and_CC contaminated_JJ operations_NNS ,_, are_VBP well_RB known_VBN ._SENT However_RB ,_, the_DT relationship_NN between_IN intraoperative_JJ antibiotic_JJ concentrations_NNS and_CC postoperative_JJ infection_NN and_CC the_DT concentrations_NNS required_VBN for_IN effective_JJ prophylaxis_NN have_VBP not_RB been_VBN established_VBN ._SENT Over_IN the_DT past_JJ decade_NN ,_, pharmacodynamic_JJ research_NN has_VBZ advanced_VBN the_DT treatment_NN of_IN infectious_JJ diseases_NNS by_IN characterizing_VBG relationships_NNS between_IN antibiotic_JJ concentrations_NNS and_CC clinical_JJ response_NN ._SENT Although_IN the_DT application_NN of_IN similar_JJ principles_NNS to_TO surgical_JJ prophylaxis_NN has_VBZ been_VBN suggested_VBN ,_, there_EX is_VBZ a_DT notable_JJ lack_NN of_IN supportive_JJ study_NN ._SENT It_PP is_VBZ probable_JJ that_IN low_JJ antibiotic_JJ concentrations_NNS during_IN surgery_NN due_JJ to_TO inappropriate_JJ timing_NN of_IN the_DT preoperative_JJ antibiotic_NN ,_, prolonged_JJ surgery_NN ,_, and_CC patient_JJ obesity_NN contribute_VB to_TO the_DT high_JJ infection_NN rates_NNS associated_VBN with_IN these_DT factors_NNS ._SENT However_RB ,_, the_DT direct_JJ effect_NN of_IN intraoperative_JJ antibiotic_JJ concentrations_NNS on_IN surgical_JJ outcome_NN has_VBZ been_VBN largely_RB overlooked_VBN by_IN clinical_JJ studies_NNS ,_, which_WDT have_VBP not_RB included_VBN this_DT variable_NN in_IN risk_NN factor_NN analyses_NNS ._SENT Pharmacodynamic_JJ data_NNS which_WDT characterize_VBP effective_JJ antibiotic_JJ concentrations_NNS during_IN surgery_NN could_MD change_VB the_DT approach_NN to_TO surgical_JJ prophylaxis_NN ._SENT In_IN a_DT previous_JJ prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ clinical_JJ study_NN ,_, regimens_NNS of_IN single_JJ high_JJ doses_NNS of_IN gentamicin_NN (_( 4.5_CD mg/kg_NN of_IN body_NN weight_NN preoperatively_NN )_) and_CC of_IN multiple_JJ standard_JJ doses_NNS of_IN gentamicin_NN (_( 1.5_CD mg/kg_NN preoperatively_RB and_CC at_IN 8_CD ,_, 16_CD ,_, and_CC 24_CD h_NN postoperatively_RB )_) ,_, both_CC in_IN combination_NN with_IN metronidazole_NN ,_, were_VBD compared_VBN for_IN prophylaxis_NN in_IN connection_NN with_IN colorectal_JJ surgery_NN ._SENT Several_JJ observations_NNS suggested_VBD an_DT association_NN between_IN low_JJ serum_NN gentamicin_NN concentrations_NNS during_IN surgery_NN and_CC clinical_JJ failure_NN ._SENT First_RB ,_, a_DT trend_NN towards_IN fewer_JJR wound_NN infections_NNS in_IN the_DT high-dose_NN group_NN suggested_VBD improved_VBN efficacy_NN when_WRB higher_JJR antibiotic_NN concentrations_NNS were_VBD achieved_VBN during_IN surgery_NN ._SENT Second_RB ,_, a_DT strong_JJ association_NN between_IN prolonged_JJ surgery_NN ,_, which_WDT is_VBZ a_DT well-documented_JJ risk_NN factor_NN ,_, and_CC infection_NN in_IN the_DT standard-dose_NN but_CC not_RB in_IN the_DT high-dose_NN group_NN also_RB supported_VBD an_DT association_NN between_IN intraoperative_JJ antibiotic_JJ concentrations_NNS and_CC clinical_JJ outcome_NN ._SENT Our_PP$ goal_NN was_VBD to_TO conduct_VB a_DT pharmacodynamic_JJ analysis_NN of_IN data_NNS from_IN the_DT original_JJ clinical_JJ study_NN to_TO characterize_VB the_DT relationship_NN between_IN intraoperative_JJ gentamicin_NN concentrations_NNS and_CC the_DT development_NN of_IN wound_NN infection_NN following_VBG colorectal_JJ surgery_NN ._SENT To_TO our_PP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ such_JJ study_NN in_IN the_DT area_NN of_IN surgical_JJ prophylaxis_NN ._SENT Previous_JJ clinical_JJ study_NN ._SENT |_SYM Data_NP were_VBD obtained_VBN from_IN a_DT previous_JJ prospective_JJ ,_, randomized_VBD ,_, double-blind_JJ clinical_JJ study_NN (_( number_NN of_IN patients_NNS ,_, 146_CD )_) of_IN antibiotic_JJ prophylaxis_NN for_IN elective_JJ colorectal_JJ surgery_NN ._SENT Study_NN treatments_NNS consisted_VBN of_IN either_DT single_JJ high_JJ doses_NNS of_IN gentamicin_NN (_( 4.5_CD mg/kg_NN )_) plus_CC metronidazole_NN (_( 500_CD mg_NN )_) preoperatively_NN or_CC multiple_JJ standard_JJ doses_NNS of_IN gentamicin_NN (_( 1.5_CD mg/kg_NN )_) plus_CC metronidazole_NN (_( 500_CD mg_NN )_) preoperatively_RB and_CC at_IN 8_CD ,_, 16_CD ,_, and_CC 24_CD h_NN postoperatively_RB ._SENT Only_RB those_DT patients_NNS with_IN serum_NN creatinine_NN levels_NNS of_IN less_JJR than_IN 150_CD mumol/liter_NN were_VBD enrolled_VBN in_IN the_DT clinical_JJ study_NN ._SENT Gentamicin_NN doses_NNS were_VBD based_VBN on_IN actual_JJ body_NN weight_NN or_CC on_IN dosing_VBG weight_NN for_IN subjects_NNS weighing_VBG more_JJR than_IN 120_CD %_NN of_IN their_PP$ ideal_JJ body_NN weight_NN ._SENT Dosing_VBG weights_NNS were_VBD calculated_VBN according_VBG to_TO the_DT formula_NN [_SYM 0.40_CD x_NN (_( actual_JJ body_NN weight_NN -_: ideal_JJ body_NN weight_NN )_) ]_SYM +_SYM ideal_JJ body_NN weight_NN ._SENT The_DT ideal_JJ body_NN weight_NN was_VBD defined_VBN as_IN 50_CD kg_NN plus_IN 2.3_CD kg_NN for_IN each_DT inch_NN of_IN height_NN over_IN 5_CD ft_NNS for_IN males_NNS and_CC 45.5_CD kg_NN plus_IN 2.3_CD kg_NN for_IN each_DT inch_NN of_IN height_NN over_IN 5_CD ft_NNS for_IN females_NNS ._SENT Metronidazole_NN and_CC gentamicin_NN were_VBD infused_VBN over_IN 30_CD min_NN and_CC administered_VBN sequentially_RB ._SENT All_DT patients_NNS received_VBD polyethelene_NP glycol_NN electrolyte_NN lavage_NN (_( Golytely_NP ;_: Baxter_NP Corp._NP ,_, Mississauga_NP ,_, Ontario_NP ,_, Canada_NP )_) or_CC phosphate_NN soda_NN solution_NN (_( Phosphasoda_NP ;_: Merck_NP Frosst_NP Canada_NP Inc._NP ,_, Pointe_NP Claire_NP ,_, Quebec_NP ,_, Canada_NP )_) the_DT day_NN prior_RB to_TO surgery_NN ._SENT The_DT primary_JJ clinical_JJ outcome_NN was_VBD the_DT development_NN of_IN surgical_JJ site_NN infection_NN within_IN 30_CD days_NNS of_IN surgery_NN ._SENT Incisional_JJ infections_NNS were_VBD classified_VBN according_VBG to_TO the_DT Centers_NPS for_IN Disease_NP Control_NP 's_POS standard_JJ definitions_NNS of_IN superficial_JJ infections_NNS involving_VBG skin_NN or_CC subcutaneous_JJ tissues_NNS and_CC deep_JJ infections_NNS involving_VBG deep_JJ tissue_NN ,_, including_VBG fascia_NN or_CC muscle_NN ._SENT Subjects_NNS were_VBD monitored_VBN for_IN systemic_JJ (_( e.g._FW ,_, fever_NN ,_, chills_NNS ,_, or_CC leukocytosis_NN )_) and_CC local_JJ (_( e.g._FW ,_, erythema_NN ,_, swelling_VBG ,_, or_CC purulent_JJ drainage_NN )_) signs_NNS of_IN infection_NN ._SENT Pharmacokinetics_NP ._SENT |_SYM Two_NP blood_NN samples_NNS were_VBD collected_VBN from_IN the_DT first_JJ 35_CD participants_NNS after_IN the_DT administration_NN of_IN the_DT preoperative_JJ gentamicin_NN dose_NN ._SENT The_DT first_JJ sample_NN was_VBD drawn_VBN at_IN least_JJS 30_CD min_NN after_IN the_DT infusion_NN ,_, and_CC the_DT second_JJ sample_NN was_VBD collected_VBN in_IN the_DT recovery_NN room_NN ._SENT Concentrations_NNS of_IN gentamicin_NN in_IN serum_NN were_VBD measured_VBN by_IN fluorescence_NN immunoassay_NN (_( TDx_NP ;_: Abbott_NP ,_, Chicago_NP ,_, Ill._NP )_) ._SENT The_DT limit_NN of_IN detection_NN was_VBD 0.2_CD mug/liter_NN ,_, and_CC the_DT coefficients_NNS of_IN variation_NN were_VBD 10.8_CD %_NN at_IN 2.2_CD mug/liter_NN and_CC 6.5_CD %_NN at_IN 13.4_CD mug/liter_NN ._SENT The_DT gentamicin_NN assay_NN results_NNS were_VBD concealed_VBN until_IN the_DT end_NN of_IN the_DT study_NN ._SENT A_DT reference_NN group_NN (_( n_NN =_SYM 16_CD )_) of_IN subjects_NNS was_VBD constructed_VBN ;_: for_IN this_DT group_NN ,_, two_CD measurements_NNS of_IN serum_NN gentamicin_NN concentrations_NNS from_IN appropriately_RB collected_VBN blood_NN samples_NNS were_VBD available_JJ ._SENT Parameters_NNS ,_, including_VBG the_DT elimination_NN rate_NN constant_JJ (_( kel_NN )_) and_CC volume_NN of_IN distribution_NN (_( V_CD )_) ,_, were_VBD calculated_VBN by_IN using_VBG a_DT one-compartment_NN ,_, linear_JJ pharmacokinetic_JJ model_NN ._SENT Correlations_NNS between_IN estimated_JJ creatinine_NN clearance_NN (_( CLCR_NP )_) and_CC kel_NN and_CC between_IN weight_NN and_CC V_CD were_VBD determined_VBN by_IN linear_JJ regression_NN analysis_NN ._SENT A_DT validation_NN group_NN (_( n_NN =_SYM 19_CD )_) was_VBD composed_VBN of_IN subjects_NNS other_JJ than_IN those_DT in_IN the_DT reference_NN group_NN ,_, with_IN at_IN least_JJS one_CD measurement_NN of_IN gentamicin_NN concentration_NN ._SENT These_DT individuals_NNS were_VBD excluded_VBN from_IN the_DT reference_NN group_NN because_IN samples_NNS were_VBD not_RB collected_VBN in_IN 1_CD case_NN ,_, drawn_VBN too_RB close_JJ to_TO the_DT administration_NN of_IN the_DT dose_NN in_IN 12_CD cases_NNS ,_, drawn_VBN too_RB closely_RB together_RB in_IN 4_CD cases_NNS ,_, and_CC not_RB documented_VBN in_IN 2_CD cases_NNS ._SENT The_DT pharmacokinetic_JJ model_NN was_VBD derived_VBN from_IN data_NNS from_IN the_DT reference_NN group_NN and_CC was_VBD tested_VBN with_IN the_DT validation_NN group_NN ._SENT The_DT model_NN was_VBD then_RB used_VBN to_TO construct_VB profiles_NNS of_IN serum_NN gentamicin_NN concentration_NN versus_IN time_NN and_CC to_TO predict_VB the_DT concentration_NN at_IN the_DT time_NN of_IN incision_NN ,_, the_DT concentration_NN at_IN the_DT time_NN of_IN closure_NN ,_, and_CC the_DT area_NN under_IN the_DT concentration-versus-time_JJ curve_NN during_IN surgery_NN (_( AUCsurg_NP )_) for_IN all_DT other_JJ subjects_NNS ._SENT Pharmacodynamics_NNS ._SENT |_SYM Separate_NN risk_NN factor_NN analyses_NNS were_VBD conducted_VBN with_IN the_DT high-dose_NN and_CC standard-dose_NN groups_NNS ._SENT Univariate_JJ analyses_NNS were_VBD used_VBN to_TO test_VB standard_JJ variables_NNS (_( i.e._FW ,_, age_NN ,_, gender_NN ,_, weight_NN ,_, inflammatory_JJ bowel_NN disease_NN ,_, malignancy_NN ,_, diabetes_NN mellitus_NN ,_, chronic_JJ corticosteroid_NN use_NN ,_, surgeon_NN ,_, operation_NN ,_, stoma_NN ,_, intraoperative_JJ core_NN temperature_NN ,_, timing_NN of_IN the_DT preoperative_JJ antibiotic_NN ,_, and_CC surgery_NN duration_NN )_) in_IN addition_NN to_TO pharmacodynamics_NN parameters_NNS (_( i.e._FW ,_, gentamicin_NN concentration_NN at_IN the_DT time_NN of_IN incision_NN ,_, concentration_NN at_IN closure_NN ,_, and_CC AUCsurg_NP )_) ._SENT Two-tailed_JJ t_NN tests_NNS were_VBD used_VBN for_IN continuous_JJ data_NNS ,_, Wilcoxon_NP rank_NN tests_NNS were_VBD used_VBN for_IN ordinal_JJ data_NNS ,_, and_CC Fisher_NP 's_POS exact_JJ or_CC chi-square_JJ tests_NNS were_VBD used_VBN for_IN nominal_JJ variables_NNS (_( alpha_NN =_SYM 0.05_CD )_) ._SENT Multivariate_JJ logistic_JJ regression_NN analysis_NN with_IN backward_JJ elimination_NN was_VBD used_VBN to_TO identify_VB independent_JJ risk_NN factors_NNS ._SENT The_DT polynomial_JJ equation_NN from_IN the_DT model_NN was_VBD then_RB used_VBN to_TO predict_VB the_DT probability_NN of_IN infection_NN as_RB follows_VBZ :_: Receiver_NN operating_VBG characteristic_JJ (_( ROC_NP )_) curves_NNS were_VBD used_VBN to_TO further_RBR analyze_VB significant_JJ gentamicin_NN concentration_NN parameters_NNS ._SENT All_DT statistical_JJ analyses_NNS were_VBD performed_VBN with_IN SPSS_NP for_IN Windows_NP ,_, release_NN 10_CD (_( SPSS_NP Inc._NP ,_, Chicago_NP ,_, Ill._NP )_) ._SENT FIG._NN 1_CD ._SENT |_SYM Profile_NP of_IN serum_NN gentamicin_NN concentration_NN versus_CC time_NN (_( Cinc_NP ,_, incision_NN concentration_NN ;_: Cclos_NP ,_, closure_NN concentrations_NNS )_) ._SENT Profile_NN of_IN serum_NN gentamicin_NN concentration_NN versus_CC time_NN (_( Cinc_NP ,_, incision_NN concentration_NN ;_: Cclos_NP ,_, closure_NN concentrations_NNS )_) ._SENT Twelve_CD of_IN the_DT clinical_JJ study_NN participants_NNS were_VBD excluded_VBN because_IN the_DT timing_NN of_IN the_DT preoperative_JJ antibiotic_NN was_VBD not_RB documented_VBN ._SENT Therefore_RB ,_, 134_CD subjects_NNS ,_, of_IN which_WDT 68_CD received_VBD the_DT high-dose_NN regimen_NN and_CC 66_CD received_VBD the_DT standard-dose_JJ regimen_NN ,_, were_VBD included_VBN in_IN the_DT pharmacodynamic_JJ study_NN ._SENT As_IN shown_VBN in_IN Table_NP ,_, there_EX were_VBD no_DT significant_JJ differences_NNS in_IN characteristics_NNS between_IN the_DT high-dose_NN and_CC standard-dose_NN regimens_NNS ._SENT Pharmacokinetics_NP ._SENT |_SYM In_IN the_DT reference_NN group_NN (_( n_NN =_SYM 16_CD )_) ,_, the_DT mean_JJ kel_NN was_VBD 0.34_CD h-1_NN (_( 95_CD %_NN confidence_NN interval_NN [_SYM CI95_NP ]_SYM ,_, 0.29_CD to_TO 0.39_CD h-1_NN )_) ,_, which_WDT corresponds_VBZ to_TO a_DT mean_JJ harmonic_JJ half-life_NN of_IN 2_CD h_NN ,_, and_CC the_DT mean_JJ V_CD was_VBD 0.23_CD liter/kg_NN (_( CI95_NP ,_, 0.19_CD to_TO 0.26_CD liter/kg_NN )_) ._SENT The_DT pharmacokinetic_JJ model_NN was_VBD described_VBN by_IN the_DT following_VBG equations_NNS :_: In_IN the_DT validation_NN analysis_NN ,_, the_DT pharmacokinetic_JJ model_NN showed_VBD excellent_JJ correlations_NNS between_IN predicted_VBN and_CC measured_VBN serum_NN gentamicin_NN concentrations_NNS (_( r2_NN =_SYM 0.85_CD )_) ,_, with_IN good_JJ measures_NNS of_IN precision_NN (_( 0.92_CD mg/liter_NN )_) and_CC bias_NN (_( 0.031_CD mg/liter_NN )_) ._SENT The_DT gentamicin_NN concentration_NN parameters_NNS measured_VBN for_IN the_DT reference_NN group_NN and_CC predicted_VBD for_IN all_DT other_JJ subjects_NNS are_VBP provided_VBN in_IN Table_NP ._SENT Pharmacodynamics_NNS ._SENT |_SYM In_IN univariate_JJ analyses_NNS ,_, several_JJ risk_NN factors_NNS for_IN infection_NN were_VBD identified_VBN in_IN the_DT standard-dose_JJ group_NN but_CC none_NN were_VBD observed_VBN in_IN the_DT high-dose_NN group_NN ._SENT In_IN the_DT standard-dose_JJ group_NN ,_, the_DT gentamicin_NN concentration_NN at_IN the_DT time_NN of_IN closure_NN (_( P_NN =_SYM 0.001_CD )_) ,_, the_DT concentration_NN at_IN incision_NN (_( P_NN =_SYM 0.001_CD )_) ,_, the_DT surgery_NN duration_NN (_( P_NN =_SYM 0.001_CD )_) ,_, the_DT presence_NN of_IN diabetes_NN mellitus_NN (_( P_NN =_SYM 0.003_CD )_) ,_, the_DT presence_NN of_IN stoma_NN (_( P_NN =_SYM 0.03_CD )_) ,_, and_CC the_DT timing_NN of_IN the_DT preoperative_JJ antibiotic_NN (_( P_NN =_SYM 0.03_CD )_) were_VBD associated_VBN with_IN infection_NN ._SENT As_RB detailed_JJ in_IN Table_NP ,_, however_RB ,_, only_RB the_DT gentamicin_NN concentration_NN at_IN closure_NN (_( P_NN =_SYM 0.02_CD )_) and_CC the_DT presence_NN of_IN diabetes_NN mellitus_NN (_( P_NN =_SYM 0.02_CD ;_: odds_NNS ratio_NN ,_, 18.2_CD ;_: CI95_NP ,_, 1.7_CD to_TO 193.8_CD )_) ,_, stoma_NN (_( P_NN =_SYM 0.04_CD ;_: odds_NNS ratio_NN ,_, 4.3_CD ;_: CI95_NP ,_, 1.1_CD to_TO 17.3_CD )_) ,_, and_CC advanced_JJ age_NN (_( P_NN =_SYM 0.05_CD )_) were_VBD independent_JJ risk_NN factors_NNS for_IN infection_NN ._SENT A_DT concentration_NN at_IN closure_NN of_IN less_JJR than_IN 0.5_CD mg/liter_NN in_IN 10_CD participants_NNS was_VBD associated_VBN with_IN an_DT 80_CD %_NN infection_NN rate_NN (_( P_NN =_SYM 0.003_CD ;_: odds_NNS ratio_NN ,_, 2.8_CD )_) ._SENT The_DT overall_JJ probability_NN of_IN infection_NN is_VBZ described_VBN by_IN the_DT following_VBG equation_NN :_: where_WRB the_DT values_NNS for_IN diabetes_NN and_CC stoma_NN were_VBD equal_JJ to_TO 1_CD if_IN present_JJ and_CC 0_CD if_IN absent_JJ ._SENT Figure_NN simulates_VBZ the_DT effect_NN of_IN the_DT gentamicin_NN concentration_NN at_IN closure_NN on_IN the_DT probability_NN of_IN surgical_JJ site_NN infection_NN in_IN a_DT representative_JJ 57-year-old_JJ patient_NN population_NN ._SENT ROC_NN curve_NN analysis_NN identified_VBD a_DT critical_JJ value_NN for_IN the_DT gentamicin_NN concentration_NN at_IN closure_NN of_IN 1.6_CD mg/liter_NN for_IN effective_JJ surgical_JJ prophylaxis_NN (_( P_NN =_SYM 0.002_CD ,_, sensitivity_NN =_SYM 70.8_CD %_NN ,_, specificity_NN =_SYM 65.9_CD %_NN )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Predicted_JJ versus_CC observed_JJ serum_NN gentamicin_NN concentrations_NNS (_( mg/liter_NN )_) in_IN the_DT validation_NN analysis_NN (_( n_NN =_SYM 19_CD )_) ._SENT Predicted_VBN versus_CC observed_VBN serum_NN gentamicin_NN concentrations_NNS (_( mg/liter_NN )_) in_IN the_DT validation_NN analysis_NN (_( n_NN =_SYM 19_CD )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Probability_NN of_IN postoperative_JJ wound_NN infection_NN and_CC gentamicin_NN concentration_NN at_IN closure_NN ._SENT Probability_NN of_IN postoperative_JJ wound_NN infection_NN and_CC gentamicin_NN concentration_NN at_IN closure_NN ._SENT TABLE_NN 1_CD |_SYM Patient_NP characteristics_NNS TABLE_NP 2_CD |_SYM Gentamicin_NP concentration_NN parameters_NNS TABLE_NP 3_CD |_SYM Independent_JJ risk_NN factors_NNS for_IN infection_NN in_IN the_DT standard-dose_JJ group_NN Although_IN the_DT goal_NN of_IN surgical_JJ prophylaxis_NN is_VBZ to_TO maintain_VB adequate_JJ antibiotic_JJ exposure_NN during_IN surgery_NN ,_, research_NN establishing_VBG effective_JJ intraoperative_JJ concentrations_NNS has_VBZ not_RB been_VBN conducted_VBN ._SENT This_DT study_NN provides_VBZ new_JJ and_CC important_JJ information_NN on_IN antibiotic_JJ pharmacodynamics_NNS in_IN surgical_JJ prophylaxis_NN ._SENT In_IN the_DT standard-dose_JJ group_NN ,_, the_DT risk_NN of_IN wound_NN infection_NN was_VBD dependent_JJ on_IN the_DT gentamicin_NN concentration_NN at_IN closure_NN and_CC on_IN the_DT presence_NN of_IN diabetes_NN mellitus_NN ,_, stoma_NN ,_, and_CC ,_, to_TO a_DT lesser_JJR degree_NN ,_, advanced_JJ age_NN ._SENT Other_JJ well-established_JJ risk_NN factors_NNS ,_, including_VBG the_DT timing_NN of_IN preoperative_JJ antibiotic_NN and_CC surgery_NN duration_NN ,_, were_VBD identified_VBN in_IN univariate_JJ tests_NNS but_CC were_VBD not_RB independently_RB associated_VBN with_IN infection_NN ._SENT The_DT identification_NN of_IN the_DT gentamicin_NN concentration_NN at_IN closure_NN as_IN an_DT independent_JJ variable_NN suggests_VBZ that_IN a_DT low_JJ antibiotic_JJ concentration_NN was_VBD the_DT predominant_JJ risk_NN associated_VBN with_IN inappropriate_JJ timing_NN of_IN the_DT preoperative_JJ antibiotic_NN and_CC with_IN prolonged_JJ surgery_NN ._SENT Notably_RB ,_, no_DT risk_NN factors_NNS for_IN infection_NN were_VBD identified_VBN in_IN the_DT otherwise-matched_JJ ,_, high-dose_NN group_NN ._SENT This_DT result_NN could_MD represent_VB a_DT gentamicin_NN dose_NN (_( i.e._FW ,_, 4.5_CD mg/kg_NN )_) that_WDT produced_VBD adequate_JJ concentrations_NNS at_IN closure_NN for_IN surgical_JJ prophylaxis_NN and_CC which_WDT therefore_RB did_VBD not_RB characterize_VB the_DT relationship_NN between_IN low_JJ antibiotic_JJ concentrations_NNS and_CC clinical_JJ failure_NN ._SENT Furthermore_RB ,_, neither_DT timing_NN of_IN preoperative_JJ antibiotic_NN nor_CC surgery_NN duration_NN was_VBD significantly_RB associated_VBN with_IN infection_NN in_IN the_DT high-dose_NN group_NN ._SENT This_DT could_MD also_RB indicate_VB that_IN the_DT gentamicin_NN dose_NN achieved_VBD sufficient_JJ intraoperative_JJ concentrations_NNS even_RB in_IN cases_NNS where_WRB the_DT timing_NN of_IN the_DT preoperative_JJ antibiotic_JJ administration_NN was_VBD too_RB early_JJ or_CC the_DT surgery_NN duration_NN was_VBD prolonged_JJ ._SENT In_IN the_DT treatment_NN of_IN infectious_JJ diseases_NNS ,_, antibiotic_JJ concentrations_NNS are_VBP usually_RB related_VBN to_TO the_DT pathogen_NN and_CC its_PP$ susceptibility_NN ,_, as_RB indicated_VBN by_IN the_DT MIC_NN ._SENT Pharmacodynamic_JJ indices_NN such_JJ as_IN the_DT peak_JJ concentration-to-MIC_JJ ratio_NN ,_, time_NN above_IN MIC_NP ,_, and_CC AUC_NP divided_VBN by_IN MIC_NP are_VBP analyzed_VBN to_TO identify_VB those_DT which_WDT best_JJS correlate_VBP with_IN the_DT eradication_NN of_IN microbes_NNS or_CC with_IN clinical_JJ cure_NN ._SENT The_DT application_NN of_IN such_JJ principles_NNS to_TO the_DT prevention_NN of_IN infection_NN is_VBZ uncertain_JJ ._SENT However_RB ,_, this_DT study_NN shows_VBZ the_DT importance_NN of_IN gentamicin_NN concentrations_NNS at_IN surgical_JJ closure_NN and_CC identifies_VBZ a_DT critical_JJ value_NN of_IN 1.6_CD mg/liter_NN for_IN effective_JJ prophylaxis_NN ._SENT This_DT suggests_VBZ that_IN standard_JJ gentamicin_NN doses_NNS ,_, as_RB used_VBN in_IN our_PP$ clinical_JJ study_NN ,_, may_MD be_VB suboptimal_JJ for_IN colorectal_JJ operations_NNS ._SENT For_IN example_NN ,_, a_DT 1.5-mg/kg_JJ preoperative_JJ gentamicin_NN dose_NN would_MD require_VB a_DT second_JJ dose_NN in_IN 3.8_CD h_NN to_TO maintain_VB concentrations_NNS above_IN 1.6_CD mg/liter_NN (_( assuming_VBG a_DT patient_NN weighing_VBG 70_CD kg_NN ,_, a_DT kel_NN of_IN 0.35_CD h-1_NN ,_, and_CC a_DT V_NN of_IN 0.25_CD liter/kg_NN )_) ._SENT A_DT 4.5-mg/kg_JJ dose_NN would_MD extend_VB the_DT coverage_NN to_TO 6.9_CD h_NN ,_, which_WDT may_MD be_VB more_RBR appropriate_JJ for_IN operations_NNS with_IN a_DT mean_JJ duration_NN exceeding_VBG 3_CD h._NN The_DT critical_JJ gentamicin_NN concentration_NN of_IN 1.6_CD mg/liter_NN must_MD be_VB interpreted_VBN with_IN some_DT caution_NN ._SENT First_RB ,_, the_DT value_NN was_VBD determined_VBN for_IN a_DT specific_JJ antibiotic_NN and_CC patient_JJ population_NN and_CC may_MD not_RB apply_VB to_TO other_JJ operations_NNS ,_, for_IN example_NN ._SENT Second_RB ,_, it_PP was_VBD derived_VBN from_IN a_DT retrospective_JJ analysis_NN of_IN clinical_JJ study_NN data_NNS and_CC therefore_RB may_MD have_VB been_VBN influenced_VBN by_IN the_DT range_NN of_IN intraoperative_JJ concentrations_NNS available_JJ ._SENT Although_IN a_DT prospective_JJ investigation_NN of_IN preselected_JJ and_CC targeted_JJ antibiotic_JJ concentrations_NNS would_MD provide_VB the_DT most_RBS complete_JJ pharmacodynamic_JJ characterization_NN ,_, it_PP would_MD also_RB require_VB the_DT deliberate_JJ administration_NN of_IN low_JJ ,_, presumably_RB ineffective_JJ ,_, doses_NNS resulting_VBG in_IN clinical_JJ failure_NN ._SENT This_DT method_NN of_IN study_NN has_VBZ obvious_JJ ethical_JJ barriers_NNS ._SENT One_CD limitation_NN of_IN this_DT study_NN was_VBD the_DT application_NN of_IN pharmacokinetic_JJ data_NNS from_IN a_DT reference_NN group_NN to_TO all_DT other_JJ subjects_NNS ._SENT However_RB ,_, the_DT pharmacokinetic_JJ model_NN produced_VBD pharmacokinetic_JJ parameters_NNS that_WDT were_VBD within_IN expected_VBN ranges_NNS and_CC that_DT demonstrated_VBN excellent_JJ predictive_JJ performance_NN in_IN the_DT validation_NN analysis_NN ._SENT The_DT model_NN described_VBD a_DT relatively_RB homogenous_JJ population_NN of_IN participants_NNS with_IN normal_JJ renal_JJ function_NN who_WP were_VBD admitted_VBN for_IN elective_JJ surgery_NN ._SENT This_DT study_NN was_VBD based_VBN on_IN the_DT assumption_NN that_IN bacterial_JJ wound_NN infections_NNS are_VBP located_VBN in_IN interstitial_JJ spaces_NNS and_CC that_IN concentrations_NNS in_IN serum_NN reflect_VBP those_DT in_IN interstitial_JJ fluids_NNS ._SENT First_RB ,_, clean_JJ incisional_JJ sites_NNS and_CC other_JJ uninfected_JJ tissues_NNS are_VBP represented_VBN by_IN high_JJ ratios_NNS of_IN surface_NN area_NN to_TO volume_NN and_CC by_IN rapid_JJ equilibration_NN of_IN antibiotic_JJ levels_NNS between_IN serum_NN and_CC wound_NN fluid_NN ._SENT The_DT use_NN of_IN gentamicin_NN ,_, with_IN low_JJ protein_NN binding_NN and_CC rapid_JJ distribution_NN into_IN extracellular_JJ fluid_NN ,_, further_RBR justifies_VBZ the_DT use_NN of_IN concentrations_NNS in_IN serum_NN to_TO approximate_VB intraoperative_JJ levels_NNS in_IN tissue_NN ._SENT This_DT study_NN demonstrates_VBZ the_DT critical_JJ effect_NN of_IN antibiotic_JJ concentration_NN at_IN closure_NN on_IN wound_NN infection_NN following_VBG colorectal_JJ surgery_NN ._SENT The_DT results_NNS also_RB suggest_VBP a_DT significant_JJ association_NN between_IN low_JJ concentrations_NNS and_CC high_JJ infection_NN rates_NNS found_VBN with_IN other_JJ well-established_JJ risk_NN factors_NNS ._SENT Finally_RB ,_, this_DT study_NN shows_VBZ the_DT value_NN of_IN pharmacodynamic_JJ research_NN in_IN surgical_JJ prophylaxis_NN and_CC the_DT need_NN for_IN investigations_NNS of_IN other_JJ antibiotics_NNS for_IN colorectal_JJ and_CC other_JJ operations_NNS ._SENT 